Text Size

Development of a Noninvasive Method of Evaluation of Pulmonary Inflammation in the Condensates of Exhaled Air

This study has been terminated.
(Technical problem)
Sponsor:
Information provided by:
University Hospital, Tours
ClinicalTrials.gov Identifier:
NCT00356629
First received: July 25, 2006
Last updated: November 13, 2008
Last verified: November 2008
History of Changes
  Purpose

The aim of the study is identify biological parameters reflecting proteolytic activity in the exhaled condenstaes which might be useful to follow up pulmonary inflammation in various conditions including cystic fibrosis, COPD, asthma, tobacco exposure. Three proteases will be analyzed, i.e. elastase, proteinase 3 and cathepsin G. Results in the condensates will be compared to those obtained in sputum.


Condition
Bronchopulmonary Ignition
Condensate of Exhaled Air
Mucoviscidosis
Asthma

Study Type: Observational
Study Design: Observational Model: Case-Only
Time Perspective: Prospective
Official Title: Development of a Noninvasive Method of Evaluation of the Pulmonary Inflammation in the Condensates of Exhaled Air

Resource links provided by NLM:

U.S. FDA Resources

Further study details as provided by University Hospital, Tours:

Estimated Enrollment: 100
Study Start Date: July 2006
Estimated Study Completion Date: July 2008
Detailed Description:

5 groups of 20 individuals each: group 1 CF, group 2 COPD, group 3 asthma, group 4 tobacco exposure, group 5 control subjects.

Collection of exhaled condensates in all subjects and of sputum in subjects belonging to groups 1 and 2.

Clinical examination and PFTs in all patients.

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Sampling Method:   Non-Probability Sample
Study Population

ubjects suffering from CF, COPD, asthma and tobacco exposure

Criteria

Inclusion criteria

  • Subjects suffering from CF, COPD, asthma and tobacco exposure (groups 1 to 4) and controls (group 5)
  • aged more or equal to 18
  • stable disease
  • able to perform PFTs
  • informed consent signed
  • affiliated to french social insurance

Exclusion Criteria:

  • acute exacerbation of the disease during the last 2 weeks
  • IV or oral steroids or antibiotics during the last 2 weeks
  • hospitalization during the last 2 weeks
  • colonization by S aureus methicillin resistant and/or Burkholderia cepacia
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00356629

Locations
France
Service de Pneumologie et EFR CHRU Tours
Tours, France, 37044
Sponsors and Collaborators
University Hospital, Tours
Investigators
Principal Investigator: DIOT Patrice, Pr service de Pneumologie et EFR CHRU Tours
  More Information

Additional Information:
Related Info  This link exits the ClinicalTrials.gov site

Publications:

Responsible Party: University Hospital Tours/Jocelyne Marlière, University Hospital Tours
ClinicalTrials.gov Identifier: NCT00356629     History of Changes
Other Study ID Numbers: AOHP06-PD Air Exhalé
Study First Received: July 25, 2006
Last Updated: November 13, 2008
Health Authority: France: Ministry of Health

Keywords provided by University Hospital, Tours:
bronchopulmonary ignition
condensate of exhaled air
Mucoviscidosis
Asthma

Additional relevant MeSH terms:
Asthma
Cystic Fibrosis
Inflammation
Pneumonia
Bronchial Diseases
Respiratory Tract Diseases
Lung Diseases, Obstructive
Lung Diseases
Respiratory Hypersensitivity
 Hypersensitivity, Immediate
Hypersensitivity
Immune System Diseases
Pancreatic Diseases
Digestive System Diseases
Genetic Diseases, Inborn
Infant, Newborn, Diseases
Pathologic Processes
Respiratory Tract Infections

ClinicalTrials.gov processed this record on May 23, 2013